Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by F. Najafipour
Total Records ( 2 ) for F. Najafipour
  F. Najafipour , A. Aliasgarzadeh , M. Niafar , M. Mobaseri , N. Aghamohamadzadeh and R.S Sorkhabi
  Thalassemia major is a genetic disorder. Blood transfusion is critical for survival in these patients. Over the course of the past two and three decade’s hypertransfusion therapy in these patients has increased significant improvement in life expectancy and quality of life. Unfortunately, this type of therapy increased the frequency of complication due to iron overloud. In the past endocrine abnormalities were very common in beta-thalassemia patients but it is more common now. The aim of this study was evaluation of prevalence of endocrine disturbances in patients with thalassemia major greater than 10 years old. Fifty six patients with thalassemia major greater than 10 years enrolled. Physicians collected demographic data and history of therapies as well as menstrual history in female. Patients have been examined to determine their pubertal status and SDS of height for evaluation of short stature. For evaluation of glucose tolerance, fasting blood glucose and oral glucose tolerance test were performed. Serum level of calcium, phosphorous, thyroid stimulating hormone, free thyroxin, luteinizing hormone and follicular stimulating hormone, estradiol in girls and testosterone in boys were measured. Fifty six patients with thalassemia major 10-27 years old were evaluated. In this study prevalence of diabetes mellitus, impaired fasting glucose and impaired glucose tolerance test were 8.9, 28.6 and 7.1%, respectively. Short stature (SDS= -2) was seen in 70 of boys and 73% of girls. Hypocalcaemia and primary overt hypothyroidism were present in 41 and 16%, respectively. 14.3% of our patients have not any endocrine abnormalities. Despite recent therapy with Desferal in the management of beta-thalassemia major, the risk of secondary endocrine dysfunction remains high. Hypogonadism is one of the most frequent endocrine complications. Endocrine evaluation in patients with thalassemia major must be carried out regularly especially in those patients over the age of 10 years in tabriz.
  N. Aghamohammadzadeh , O. Mashrabi , A. Bahrami , F. Najafipour , A. Aliasgharzadeh , M.Y. Marandi , M.D.T. Rasht , M.A. Nozad and S.T. Mehrabad
  Patients with Graves` disease are usually treated with radioiodine after unsuccessful antithyroid drug medication, occurrence of side effects from antithyroid drugs or because of high risk of surgery. The aim of this study, is evaluation of the results and complications of treatment of Graves` disease with radioiodine. In a cross sectional descriptive-analytical study, 300 patients with Graves` disease who were treated with radioiodine in Endocrinology and Metabolism clinic of Tabriz Medical Sciences University between 2001-2004 were selected and followed up for one year regarding complications and response to treatment. Data analyzed by SPSS 11.5 software and T-test and Chi-Square test and the level of meaningfulness was considered as p< 0.05. 116(38.7%) of patients were male and 184(61.3%) of patients were female. Mean of age in male patients was 41.04±11.70 years and mean of age in female patients was 41.27±12.51 years (p = 0.875). Mean of radioiodine administration dosage in male patients was 13.53±4.60 mCi and in female patients was 11.53±5.03 mCi (p = 0.001).Thyroid size was significantly decreased after treatment (p = 0.000). 11(3.7%) of patients were involved to ophthalmopathy. Ophthalmopathy in two patients were intensification and in 33 patients were recovered. At one year followed up, 246(82%) of patients were euthyroidism. Treatment of Graves` disease with radioiodine is one of the most useful, safety and available treatment. Exacerbation of ophthalmopathy after radioiodine treatment was one of the most common complications. Prevalence of hypothyroidism was 18%. Radioiodine causes significant decrease in thyroid gland size.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility